| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3100 |
| Trial ID | NCT05442515 |
| Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | B-Cell Lymphoma | B-Cell Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies |
| Year | 2022 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10000324|000324-C |
| Cohort 1 | |||||||
|
|||||||